Can a new vaccine shield adults from four meningitis strains?
NCT ID NCT06131554
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial is testing an experimental vaccine called Menhycia, designed to protect against four types of meningococcal bacteria (A, C, Y, and W135) that can cause meningitis and bloodstream infections. The study involves about 1,480 healthy adults aged 18 to 55, who will receive either one dose of Menhycia or a licensed comparison vaccine. Researchers will measure the immune response and monitor for side effects to see if the new vaccine is as effective and safe as the existing one.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), also known as Menhycia
- What this could lead to
- If successful, this vaccine could offer a new option to prevent meningococcal meningitis and septicemia caused by four serogroups (A, C, Y, W135) in adults.
- What could go wrong
- This is a Phase 3 trial, but results are not yet available. The vaccine may not produce a strong enough immune response or may cause side effects. Long-term protection is also unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Husada Utama Hospital
Surabaya, 60131, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.